Outpatient medications associated with protection from COVID-19 hospitalization.

PLoS One · 2023 · PMC10065249 · PMID 37000808

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A recently completed, large factorial trial of metformin, ivermectin, and fluvoxamine in outpatients infected with COVID-19 showed a trend towards benefit with metformin, and in particular demonstrated a 42% reduction in risk of emergency department visit, hospitalization, or death [ 65 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.